These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Shamash J; Davies A; Ansell W; Mcfaul S; Wilson P; Oliver T; Powles T Br J Cancer; 2008 Jan; 98(1):22-4. PubMed ID: 18182976 [TBL] [Abstract][Full Text] [Related]
4. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. Pitts WR BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186 [No Abstract] [Full Text] [Related]
5. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ; Plowman PN Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848 [No Abstract] [Full Text] [Related]
6. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer. Higgins GS; Stewart GD; McNeill SA; McLaren DB Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800 [No Abstract] [Full Text] [Related]
7. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
8. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate]. Berenguer Sánchez A Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304 [No Abstract] [Full Text] [Related]
9. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. Scherr DS; Pitts WR J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759 [TBL] [Abstract][Full Text] [Related]
10. [Managing side effects of androgene deprivation in prostate cancer]. Thalgott M; Gschwend JE; Retz M MMW Fortschr Med; 2010 Oct; 152(41):40-3. PubMed ID: 21090376 [No Abstract] [Full Text] [Related]
11. [Reevaluation and potential therapeutic effects of estrogen therapy to prostate cancer patients]. Kato M; Kase H; Okada K; Tohma T; Ishiwata D Nihon Rinsho; 1998 Aug; 56(8):2140-4. PubMed ID: 9750523 [TBL] [Abstract][Full Text] [Related]
15. [ST52 treatment of cancer of the prostate during the hormonal resistance phase]. Grise P; Mnif A; Navarra S; Foulatier O; Barret E; Sibert L; Pfister C Ann Urol (Paris); 1998; 32(1):39-44. PubMed ID: 9559075 [TBL] [Abstract][Full Text] [Related]
16. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. Tsukamoto S; Akaza H Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC; Wildschutz TP Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814 [No Abstract] [Full Text] [Related]
18. Endocrine approaches in the therapy of prostate carcinoma. d'Ancona FC; Debruyne FM Hum Reprod Update; 2005; 11(3):309-17. PubMed ID: 15790600 [TBL] [Abstract][Full Text] [Related]
19. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer]. Kawai K; Akaza H Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517 [TBL] [Abstract][Full Text] [Related]